ABBOTT LABORATORIES (ABT) EBITDA
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $1.34B; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $2.06B; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $2.05B; Depreciation and amortization (m).
- 2025-03-31: Basis Reported; EBITDA (m); Operating income $1.69B; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Reported | (m) | $1.34B | (m) | $11.16B | (m) | $399.00M | $1.31B | $4.89B | $767.00M | $3.74B | $372.00M |
| 2025-09-30 | Reported | (m) | $2.06B | (m) | $11.37B | (m) | $496.00M* | $2.79B* | $5.08B | $766.00M | $3.05B | $536.00M |
| 2025-06-30 | Reported | (m) | $2.05B | (m) | $11.14B | (m) | $502.00M* | $2.05B* | $4.85B | $725.00M | $3.09B | $371.00M |
| 2025-03-31 | Reported | (m) | $1.69B | (m) | $10.36B | (m) | $484.00M | $1.42B | $4.47B | $716.00M | $3.06B | $453.00M |
| 2024-09-30 | Reported | (m) | $1.86B | (m) | $10.63B | (m) | $556.00M* | $2.71B* | $4.70B | $713.00M | $2.90B | $294.00M |
| 2024-06-30 | Reported | (m) | $1.67B | (m) | $10.38B | (m) | $533.00M* | $1.96B* | $4.60B | $698.00M | $2.94B | $305.00M |
| 2024-03-31 | Reported | (m) | $1.39B | (m) | $9.96B | (m) | $398.00M | $1.02B | $4.46B | $684.00M | $2.96B | $211.00M |
| 2023-09-30 | Reported | (m) | $1.65B | (m) | $10.14B | (m) | $560.00M* | $1.88B* | $4.61B | $672.00M | $2.72B | $235.00M |
| 2023-06-30 | Reported | (m) | $1.54B | (m) | $9.98B | (m) | $507.00M* | $1.20B* | $4.48B | $715.00M | $2.74B | $261.00M |
| 2023-03-31 | Reported | (m) | $1.51B | (m) | $9.75B | (m) | $380.00M | $1.14B | $4.33B | $654.00M | $2.76B | $244.00M |
| 2022-09-30 | Reported | (m) | $1.77B | (m) | $10.41B | (m) | $467.00M* | $2.78B* | $4.63B | $782.00M | $2.73B | $323.00M |
| 2022-06-30 | Reported | (m) | $2.38B | (m) | $11.26B | (m) | $379.00M* | $2.41B* | $4.93B | $684.00M | $2.76B | $334.00M |
| 2022-03-31 | Reported | (m) | $2.91B | (m) | $11.89B | (m) | $321.00M | $2.06B | $4.99B | $697.00M | $2.79B | $429.00M |
| 2021-09-30 | Reported | (m) | $2.55B | (m) | $10.93B | (m) | $461.00M* | $2.70B* | $4.42B | $672.00M | $2.77B | $393.00M |
| 2021-06-30 | Reported | (m) | $1.39B | (m) | $10.22B | (m) | $413.00M* | $2.13B* | $4.95B | $654.00M | $2.73B | $159.00M |
| 2021-03-31 | Reported | (m) | $2.11B | (m) | $10.46B | (m) | $397.00M | $2.64B | $4.40B | $654.00M | $2.78B | $250.00M |
| 2020-09-30 | Reported | (m) | $1.50B | (m) | $8.85B | (m) | $496.00M* | $2.07B* | $3.97B | $580.00M | $2.30B | $189.00M |
| 2020-06-30 | Reported | (m) | $672.00M | (m) | $7.33B | (m) | $642.00M* | $1.32B* | $3.26B | $564.00M | $2.28B | -$11.00M |
| 2020-03-31 | Reported | (m) | $758.00M | (m) | $7.73B | (m) | $360.00M | $715.00M | $3.28B | $578.00M | $2.55B | $89.00M |
| 2019-09-30 | Reported | (m) | $1.20B | (m) | $8.08B | (m) | $401.00M* | $1.95B* | $3.36B | $596.00M | $2.44B | $143.00M |
| 2019-06-30 | Reported | (m) | $1.21B | (m) | $7.98B | (m) | $468.00M* | $1.06B* | $3.28B | $577.00M | $2.43B | $96.00M |
| 2019-03-31 | Reported | (m) | $739.00M | (m) | $7.54B | (m) | $335.00M | $712.00M | $3.16B | $672.00M | $2.48B | -$40.00M |
| 2018-09-30 | Reported | (m) | $995.00M | (m) | $7.66B | (m) | $354.00M* | $2.18B* | $3.17B | $574.00M | $2.38B | $166.00M |
| 2018-06-30 | Reported | (m) | $882.00M | (m) | $7.77B | (m) | $298.00M* | $1.24B* | $3.28B | $575.00M | $2.47B | $59.00M |
| 2018-03-31 | Reported | (m) | $608.00M | (m) | $7.39B | (m) | $275.00M | $1.11B | $3.07B | $589.00M | $2.54B | $22.00M |
| 2017-09-30 | Reported | (m) | $769.00M | (m) | $6.83B | (m) | $263.00M* | $2.00B* | $2.88B | (m) | $2.12B | $65.00M |
| 2017-06-30 | Reported | (m) | $386.00M | (m) | $6.64B | (m) | $255.00M* | $1.35B* | $3.19B | (m) | $2.15B | $25.00M |
| 2017-03-31 | Reported | (m) | -$242.00M | (m) | $6.33B | (m) | $272.00M | $574.00M | (m) | (m) | $2.44B | $350.00M |
| 2016-09-30 | Reported | (m) | $897.00M | (m) | (m) | (m) | $312.00M* | $1.22B* | (m) | (m) | $1.63B | $178.00M |
| 2016-06-30 | Reported | (m) | $816.00M | (m) | (m) | (m) | $247.00M* | $909.00M* | (m) | (m) | $1.74B | $116.00M |
| 2016-03-31 | Reported | (m) | $524.00M | (m) | (m) | (m) | $243.00M | -$93.00M | (m) | (m) | $1.70B | -$54.00M |
| 2015-09-30 | Reported | (m) | $713.00M | (m) | (m) | (m) | $411.00M* | $1.20B* | (m) | (m) | $1.67B | $118.00M |
| 2015-06-30 | Reported | (m) | $729.00M | (m) | (m) | (m) | $216.00M* | $941.00M* | (m) | (m) | $1.73B | $200.00M |
| 2015-03-31 | Reported | (m) | $610.00M | (m) | (m) | (m) | $235.00M | $2.00M | (m) | (m) | $1.74B | $124.00M |
| 2014-09-30 | Reported | (m) | $728.00M | (m) | (m) | (m) | $277.00M* | $1.20B* | (m) | (m) | $1.59B | $277.00M |
| 2014-06-30 | Reported | (m) | $677.00M | (m) | (m) | (m) | $258.00M* | $900.00M* | (m) | (m) | $1.65B | $233.00M |
| 2014-03-31 | Reported | (m) | $365.00M | (m) | (m) | (m) | $255.00M | $336.00M | (m) | (m) | $1.62B | $117.00M |
| 2013-09-30 | Reported | (m) | $473.00M | (m) | (m) | (m) | $277.00M* | $522.00M* | (m) | (m) | $1.61B | -$163.00M |
| 2013-06-30 | Reported | (m) | $627.00M | (m) | (m) | (m) | $291.00M* | $717.00M* | (m) | (m) | $1.71B | $125.00M |
| 2013-03-31 | Reported | (m) | $615.00M | (m) | (m) | (m) | $274.00M | $460.00M | (m) | (m) | $1.79B | $10.00M |
| 2012-09-30 | Reported | (m) | $310.02M | (m) | (m) | (m) | $530.75M* | $3.52B* | (m) | (m) | $1.92B | -$107.61M |
| 2012-06-30 | Reported | (m) | $564.19M | (m) | (m) | (m) | $425.12M* | $2.07B* | (m) | (m) | $1.81B | $118.66M |
| 2012-03-31 | Reported | (m) | $509.19M | (m) | (m) | (m) | $453.33M | $2.22B | (m) | $50.00M | $1.84B | $112.16M |
| 2011-09-30 | Reported | (m) | $594.88M | (m) | (m) | (m) | $452.00M* | (m) | (m) | (m) | $4.24B | $198.41M |
| 2011-06-30 | Reported | (m) | $1.77B | (m) | (m) | (m) | $372.96M* | $2.50B* | (m) | (m) | $2.76B | -$268.23M |
| 2011-03-31 | Reported | (m) | $1.30B | (m) | (m) | (m) | $391.81M | $2.01B | (m) | (m) | $2.85B | $204.97M |
| 2010-09-30 | Reported | (m) | $1.18B | (m) | (m) | (m) | $205.09M* | $2.55B* | (m) | (m) | $2.67B | $173.45M |
| 2010-06-30 | Reported | (m) | $1.61B | (m) | (m) | (m) | $273.51M* | $2.35B* | (m) | (m) | $2.74B | $267.04M |
| 2010-03-31 | Reported | (m) | $1.47B | (m) | (m) | (m) | $245.14M | $1.52B | (m) | (m) | $2.16B | $319.19M |
| 2009-09-30 | Reported | (m) | $1.64B | (m) | (m) | (m) | $328.71M* | $3.03B* | (m) | (m) | $2.09B | $391.01M |
| 2009-06-30 | Reported | (m) | $1.67B | (m) | (m) | (m) | $262.74M* | $1.71B* | (m) | (m) | $2.02B | $278.93M |
| 2009-03-31 | Reported | (m) | $1.06B | (m) | (m) | (m) | $252.15M | $698.72M | (m) | (m) | $2.07B | $493.84M |
| 2008-09-30 | Reported | (m) | $1.40B | (m) | (m) | (m) | $319.81M* | $2.70B* | (m) | (m) | $2.07B | $288.42M |
| 2008-06-30 | Reported | (m) | $1.41B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.05B | $314.30M |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | $8.05B | (m) | $44.33B | (m) | $2.17B | $9.57B | $19.32B | $2.94B | $12.33B | $1.94B |
| 2024-12-31 | Reported | (m) | $6.83B | (m) | $41.95B | (m) | $2.21B | $8.56B | $18.71B | $2.84B | $11.70B | -$6.39B |
| 2023-12-31 | Reported | (m) | $6.48B | (m) | $40.11B | (m) | $2.20B | $7.26B | $17.98B | $2.74B | $10.95B | $941.00M |
| 2022-12-31 | Reported | (m) | $8.36B | (m) | $43.65B | (m) | $1.78B | $9.58B | $19.14B | $2.89B | $11.25B | $1.37B |
| 2021-12-31 | Reported | (m) | $8.43B | (m) | $43.08B | (m) | $1.89B | $10.53B | $18.54B | $2.74B | $11.32B | $1.14B |
| 2020-12-31 | Reported | (m) | $5.36B | (m) | $34.61B | (m) | $2.18B | $7.90B | $15.00B | $2.42B | $9.70B | $497.00M |
| 2019-12-31 | Reported | (m) | $4.53B | (m) | $31.90B | (m) | $1.64B | $6.14B | $13.23B | $2.44B | $9.77B | $390.00M |
| 2018-12-31 | Reported | (m) | $3.65B | (m) | $30.58B | (m) | $1.39B | $6.30B | $12.71B | $2.30B | $9.74B | $539.00M |
| 2017-12-31 | Reported | (m) | $1.56B | (m) | $27.39B | (m) | $1.14B | $5.57B | $12.41B | $2.26B | $9.18B | $1.88B |
| 2016-12-31 | Reported | (m) | $3.03B | (m) | $20.85B | (m) | $1.12B | $3.20B | $9.09B | (m) | $6.74B | $350.00M |
| 2015-12-31 | Reported | (m) | $2.87B | (m) | (m) | (m) | $1.11B | $2.97B | (m) | (m) | $6.79B | $577.00M |
| 2014-12-31 | Reported | (m) | $2.60B | (m) | (m) | (m) | $1.08B | $3.67B | (m) | (m) | $6.53B | $797.00M |
| 2013-12-31 | Reported | (m) | $2.13B | (m) | (m) | (m) | $1.15B | $3.32B | (m) | (m) | $6.37B | $53.00M |
| 2012-12-31 | Reported | (m) | $1.36B | (m) | (m) | (m) | $1.79B | $9.31B | (m) | (m) | $6.74B | -$457.00M |
| 2011-12-31 | Reported | (m) | $1.63B | (m) | (m) | (m) | $1.49B | $8.97B | (m) | (m) | $7.37B | $110.00M |
| 2010-12-31 | Reported | (m) | $6.09B | (m) | (m) | (m) | $1.02B | (m) | (m) | (m) | $10.38B | $1.09B |
| 2009-12-31 | Reported | (m) | $6.24B | (m) | (m) | (m) | $1.09B | (m) | (m) | (m) | $8.41B | $1.45B |
| 2008-12-31 | Reported | (m) | $5.69B | (m) | (m) | (m) | $1.29B | (m) | (m) | (m) | $8.44B | $1.12B |
| 2007-12-31 | Reported | (m) | $4.58B | (m) | (m) | (m) | $1.66B | (m) | (m) | (m) | $7.41B | $863.33M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |